Literature DB >> 15548598

HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion.

Hanane Khoury1, Monica A Naujokas, Dongmei Zuo, Veena Sangwan, Melanie M Frigault, Stephanie Petkiewicz, David L Dankort, William J Muller, Morag Park.   

Abstract

Activation of the hepatocyte growth factor receptor Met induces a morphogenic response and stimulates the formation of branching tubules by Madin-Darby canine kidney (MDCK) epithelial cells in three-dimensional cultures. A constitutively activated ErbB2/Neu receptor, NeuNT, promotes a similar invasive morphogenic program in MDCK cells. Because both receptors are expressed in breast epithelia, are associated with poor prognosis, and hepatocyte growth factor (HGF) is expressed in stroma, we examined the consequence of cooperation between these signals. We show that HGF disrupts NeuNT-induced epithelial morphogenesis, stimulating the breakdown of cell-cell junctions, dispersal, and invasion of single cells. This correlates with a decrease in junctional proteins claudin-1 and E-cadherin, in addition to the internalization of the tight junction protein ZO-1. HGF-induced invasion of NT-expressing cells is abrogated by pretreatment with a pharmacological inhibitor of the mitogen-activated protein kinase kinase (MEK) pathway, which restores E-cadherin and ZO-1 at cell-cell junctions, establishing the involvement of MEK-dependent pathways in this process. These results demonstrate that physiological signals downstream from the HGF/Met receptor synergize with ErbB2/Neu to enhance the malignant phenotype, promoting the breakdown of cell-cell junctions and enhanced cell invasion. This is particularly important for cancers where ErbB2/Neu is overexpressed and HGF is a physiological growth factor found in the stroma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15548598      PMCID: PMC545891          DOI: 10.1091/mbc.e04-07-0567

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  69 in total

1.  Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail.

Authors:  Junichi Ikenouchi; Miho Matsuda; Mikio Furuse; Shoichiro Tsukita
Journal:  J Cell Sci       Date:  2003-03-26       Impact factor: 5.285

2.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.

Authors:  D L Dankort; Z Wang; V Blackmore; M F Moran; W J Muller
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 3.  Modeling tissue-specific signaling and organ function in three dimensions.

Authors:  Karen L Schmeichel; Mina J Bissell
Journal:  J Cell Sci       Date:  2003-06-15       Impact factor: 5.285

Review 4.  Epithelial cell adhesion and the regulation of gene expression.

Authors:  Maria S Balda; Karl Matter
Journal:  Trends Cell Biol       Date:  2003-06       Impact factor: 20.808

5.  Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons.

Authors:  A Ebens; K Brose; E D Leonardo; M G Hanson; F Bladt; C Birchmeier; B A Barres; M Tessier-Lavigne
Journal:  Neuron       Date:  1996-12       Impact factor: 17.173

Review 6.  Model systems of epithelium-mesenchyme transitions.

Authors:  B Boyer; A M Vallés; J P Thiery
Journal:  Acta Anat (Basel)       Date:  1996

7.  Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney.

Authors:  C Selli; A Amorosi; G Vona; R Sestini; F Travaglini; R Bartoletti; C Orlando
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

8.  Transcriptional defects underlie loss of E-cadherin expression in breast cancer.

Authors:  X Ji; A S Woodard; D L Rimm; E R Fearon
Journal:  Cell Growth Differ       Date:  1997-07

9.  Erbb2 regulates neuromuscular synapse formation and is essential for muscle spindle development.

Authors:  Marco Leu; Elena Bellmunt; Martin Schwander; Isabel Fariñas; Hans Rudolf Brenner; Ulrich Müller
Journal:  Development       Date:  2003-06       Impact factor: 6.868

10.  Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.

Authors:  Jung Y Kang; Marisa Dolled-Filhart; Idris Tolgay Ocal; Baljit Singh; Chen-Yong Lin; Robert B Dickson; David L Rimm; Robert L Camp
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

View more
  47 in total

Review 1.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

2.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

3.  A novel role for 14-3-3sigma in regulating epithelial cell polarity.

Authors:  Chen Ling; Dongmei Zuo; Bin Xue; Senthil Muthuswamy; William J Muller
Journal:  Genes Dev       Date:  2010-05       Impact factor: 11.361

Review 4.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

Review 5.  The ErbB2 signaling network as a target for breast cancer therapy.

Authors:  Ali Badache; Anthony Gonçalves
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

6.  ARID1A knockdown triggers epithelial-mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma.

Authors:  Keerakarn Somsuan; Paleerath Peerapen; Wanida Boonmark; Sirikanya Plumworasawat; Ratirath Samol; Natthiya Sakulsak; Visith Thongboonkerd
Journal:  FASEB J       Date:  2019-08-21       Impact factor: 5.191

7.  LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.

Authors:  David L Shattuck; Jamie K Miller; Melanie Laederich; Melanie Funes; Heidi Petersen; Kermit L Carraway; Colleen Sweeney
Journal:  Mol Cell Biol       Date:  2006-12-18       Impact factor: 4.272

8.  cMET and phospho-cMET protein levels in breast cancers and survival outcomes.

Authors:  Kanwal P Raghav; Wenting Wang; Shuying Liu; Mariana Chavez-MacGregor; Xiaolong Meng; Gabriel N Hortobagyi; Gordon B Mills; Funda Meric-Bernstam; George R Blumenschein; Ana M Gonzalez-Angulo
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

9.  EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma.

Authors:  Ellie Chan; Ahmad Alkhasawneh; Lizette Vila Duckworth; Tabish Aijaz; Tania Zuluaga Toro; Xiaomin Lu; Steven J Hughes; Amy Collinsworth; Thomas J George
Journal:  J Gastrointest Oncol       Date:  2016-12

10.  Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.

Authors:  Ken Suzawa; Michael Offin; Daniel Lu; Christopher Kurzatkowski; Morana Vojnic; Roger S Smith; Joshua K Sabari; Huichun Tai; Marissa Mattar; Inna Khodos; Elisa de Stanchina; Charles M Rudin; Mark G Kris; Maria E Arcila; William W Lockwood; Alexander Drilon; Marc Ladanyi; Romel Somwar
Journal:  Clin Cancer Res       Date:  2018-10-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.